Development of a Novel Acoustic Resuscitation Monitor

新型声学复苏监测仪的开发

• 批准号: 6992571
• 负责人: JOHN Milton SEWELL
• 金额: $ 14.77万
• 依托单位: ACTIVE SIGNAL TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6992571
• 关键词: biomedical equipment development; blood circulation; blood pressure; carotid artery; clinical biomedical equipment; clinical research; critical care; hemorrhagic shock; human subject; lactates; noninvasive diagnosis; oxygen therapy; patient monitoring device; portable biomedical equipment; resuscitation; trauma; vasoconstriction

DESCRIPTION (provided by applicant): Currently almost half of all trauma mortality is directly or indirectly attributable to hemorrhagic shock, accounting for more than 50,000 deaths yearly in the U.S. and hundreds of billions of dollars in economic costs. Active Signal Technologies proposes to develop an Acoustic Resuscitation Monitor (ARM) for enabling non-invasive assessment of systemic perfusion in real time, with the ultimate goal of developing a device that can continuously monitor shock and resuscitation in the field. As no such device exists and current perfusion tests have significant lag time, ARM can significantly improve patient outcome and lower costs both for in-hospital (Phase I) and field (Phase II) settings. The ARM technology is based on Active Signal's Brain Acoustic Monitor (BAM) - demonstrated effectively in brain perfusion studies on more than 500 trauma and 100 stroke patients. In Phase I Active Signal with the University of Maryland Shock Trauma Center will conduct feasibility tests on approximately 100 patients with 5 data collection times. Specific aims are to determine the relationship between vasoconstriction as indicated by ARM using pulse-waveform characteristics and systemic perfusion measured by current clinical metrics, and to reconfigure the BAM to monitor vasoconstriction at 3 arterial tree levels.

描述（由申请人提供）：目前，所有创伤死亡率的几乎一半是直接或间接归因于出血性冲击，在美国，每年占50,000多人的死亡，经济成本数百亿美元。主动信号技术建议开发一个声音复苏监测仪（ARM），以实时对全身性灌注进行非侵入性评估，其最终目标是开发可以在该领域中连续监视冲击和复苏的设备。由于不存在此类设备，并且当前的灌注测试具有很大的滞后时间，因此ARM可以显着改善患者的预后，并且在院内（I期）和现场（II期）设置的成本较低。 ARM技术基于Active Signal的脑声监测器（BAM） - 在500多名创伤和100名中风患者的脑灌注研究中有效证明。在第一阶段的主动信号中，马里兰大学休克创伤中心将对大约100名数据收集时间的患者进行可行性测试。具体目的是确定使用脉冲波动特征和通过当前临床指标测量的全身性灌注表示的血管收缩之间的关系，并重新配置BAM以在3个动脉树水平下监测血管收缩。